[{"address1": "302, 6 Butler Street", "city": "Camberwell", "state": "VIC", "zip": "3124", "country": "Australia", "phone": "61 3 9882 0780", "fax": "61 3 9882 9969", "website": "https://www.propanc.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Ja\u00e9n, to undertakes the research activities for the POP1 Program and the University of Granada to develop a synthetic recombinant version of PRP. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.", "fullTimeEmployees": 1, "companyOfficers": [{"maxAge": 1, "name": "Dr. Julian Norman Kenyon ChB, M.D., MB", "age": 76, "title": "Chief Scientific Officer & Director", "yearBorn": 1948, "fiscalYear": 2025, "totalPay": 35481, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1767139200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 4.0, "open": 4.0, "dayLow": 2.82, "dayHigh": 4.4, "regularMarketPreviousClose": 4.0, "regularMarketOpen": 4.0, "regularMarketDayLow": 2.82, "regularMarketDayHigh": 4.4, "payoutRatio": 0.0, "beta": 19205.45, "volume": 485597, "regularMarketVolume": 485597, "averageVolume": 10072, "averageVolume10days": 51950, "averageDailyVolume10Day": 51950, "bid": 10.4, "ask": 10.4, "bidSize": 265, "askSize": 848, "marketCap": 33325864, "fiftyTwoWeekLow": 0.0004, "fiftyTwoWeekHigh": 145.46, "fiftyDayAverage": 5.977618, "twoHundredDayAverage": 4.0764666, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 34522224, "profitMargins": 0.0, "floatShares": 3134601, "sharesOutstanding": 11611800, "heldPercentInsiders": 0.71476996, "heldPercentInstitutions": 0.07751, "impliedSharesOutstanding": 18845400, "bookValue": 1.558, "priceToBook": 1.8421053, "lastFiscalYearEnd": 1719705600, "nextFiscalYearEnd": 1751241600, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -55403376, "trailingEps": -333.31, "lastSplitFactor": "1:2", "lastSplitDate": 1738108800, "enterpriseToEbitda": -0.641, "52WeekChange": 2390.6667, "SandP52WeekChange": 0.15005577, "quoteType": "EQUITY", "currentPrice": 2.87, "recommendationKey": "none", "totalCash": 50760, "totalCashPerShare": 0.004, "ebitda": -53892560, "totalDebt": 1247170, "quickRatio": 0.013, "currentRatio": 2.243, "debtToEquity": 6.893, "returnOnAssets": -2.9854598, "returnOnEquity": -7.67196, "freeCashflow": 9886640, "operatingCashflow": -637948, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "PPCB", "language": "en-US", "region": "US", "typeDisp": "Equity", "triggerable": false, "customPriceAlertConfidence": "LOW", "shortName": "Propanc Biopharma, Inc.", "longName": "Propanc Biopharma, Inc. Common Stock", "cryptoTradeable": false, "hasPrePostMarketData": false, "firstTradeDateMilliseconds": 1357569000000, "postMarketChangePercent": 18.4704, "postMarketPrice": 3.4001, "postMarketChange": 0.5301, "regularMarketChange": -1.1300001, "regularMarketDayRange": "2.82 - 4.4", "fullExchangeName": "OTC Markets OTCPK", "averageDailyVolume3Month": 10072, "fiftyTwoWeekLowChange": 2.8695998, "fiftyTwoWeekLowChangePercent": 7173.9995, "fiftyTwoWeekRange": "4.0E-4 - 145.46", "fiftyTwoWeekHighChange": -142.59001, "fiftyTwoWeekHighChangePercent": -0.98026955, "fiftyTwoWeekChangePercent": 239066.67, "dividendDate": 1605744000, "marketState": "CLOSED", "regularMarketChangePercent": -28.250004, "regularMarketPrice": 2.87, "epsTrailingTwelveMonths": -333.31, "fiftyDayAverageChange": -3.1076183, "fiftyDayAverageChangePercent": -0.5198757, "twoHundredDayAverageChange": -1.2064667, "twoHundredDayAverageChangePercent": -0.29595894, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "corporateActions": [{"header": "New Listing", "message": "PPCB is newly listed on Nasdaq effective Aug. 15, 2025", "meta": {"eventType": "NEW_LISTING", "dateEpochMs": 1755230400000, "exchange": "Nasdaq"}}], "postMarketTime": 1755302362, "regularMarketTime": 1755287990, "exchange": "PNK", "messageBoardId": "finmb_134729532", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "displayName": "Propanc Biopharma", "trailingPegRatio": null, "__fetch_time": "2025-08-16"}]